HPV16 L1 Capsid Antibody Titers and Prognosis in HPV Associated Malignancy: Oropharyngeal, Anal, Cervical and Vaginal Cancer
David M. Routman(Mayo Clinic in Arizona), Eric J. Moore(Mayo Clinic), M.C. Liu(Mayo Clinic in Arizona), Ralf Hilfrich, Katharine A. Price(WinnMed), T.A. DeWees(Mayo Clinic in Arizona), Ivy A. Petersen(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), L. Joern, Nadia N. Laack(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), Robert L. Foote(Mayo Clinic), Allison E. Garda(Mayo Clinic in Arizona), Krishan R. Jethwa(Mayo Clinic)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2019
Cited by 1
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
|Neuro-Oncology|2013|942
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
|Journal of Clinical Oncology|2020|827
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733